Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0000950170-25-096268

Chief Scientific Officer sold 8,500 shares at $14.00 ($118,962)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-07-15 Sale 10b5-1 −8,500 $14.00 $118,962 435,142 D: show line 1 in the form
Open-market sales · 8,500 sh · avg $14.00 · $118,962
Loading xslF345X05/ownership.xml…